European Pharmaceutical Review

FEBRUARY 15, 2024

A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.

Chemotherapy 105

Chemotherapy 105

Pharmafile

MARCH 4, 2024

The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)

Chemotherapy 110

Chemotherapy FDA 110

European Pharmaceutical Review

JUNE 19, 2024

A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.

Chemotherapy 98

Chemotherapy 98

Hospital Pharmacy Europe

APRIL 24, 2023

Using pembrolizumab plus gemcitabine and cisplatin improves overall survival compared to chemotherapy alone in advanced biliary tract cancer Patients with biliary tract cancers invariably present at a late stage when curative surgery is not possible. Adults were randomised 1:1 to pembrolizumab plus chemotherapy or placebo and chemotherapy.

Chemotherapy 98

Chemotherapy Hospitals 98

Pharmacy Times

MARCH 14, 2024

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

Chemotherapy 123

Chemotherapy FDA 123

Hospital Pharmacy Europe

AUGUST 10, 2023

The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The post Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy appeared first on Hospital Pharmacy Europe.

Chemotherapy 97

Chemotherapy Hospitals 97

Pharmacy Times

JULY 24, 2023

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Chemotherapy 123

Chemotherapy FDA 123

Drug Topics

NOVEMBER 8, 2022

Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.

Chemotherapy 144

Chemotherapy 144

Pharmacy Times

SEPTEMBER 2, 2022

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

Chemotherapy 156

Chemotherapy 156

Drug Topics

AUGUST 9, 2023

A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

APRIL 7, 2023

A new, sustained-release chemotherapy delivery device inserted into the bladder, facilitated tumour response, a study has reported. The intravesical device, TAR-200, provides continuous, low-dose, local delivery of gemcitabine chemotherapy. All patients had transurethral resection of bladder tumour (TURBT) to remove visible tumour.

Chemotherapy 98

Chemotherapy Mayo Clinic 98

PharmExec

JULY 15, 2024

allows Artelo to begin a Phase I study for the drug in chemotherapy-induced peripheral neuropathy. Clearance of the New Drug Application for ART25.12

Chemotherapy 52

Chemotherapy FDA 52

Fierce Pharma

JUNE 5, 2023

Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have fibroblast growth factor receptor (FGFR) gene | Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have (..)

Chemotherapy 94

Chemotherapy 94

Hospital Pharmacy Europe

AUGUST 14, 2023

A significant and increasing trend towards the use of a three-month rather than six-month adjuvant chemotherapy regime in stage 3 colon cancer has been observed following publications from the IDEA collaboration abstract. In addition, CAPOX prescribing also significantly increased from 14% to 48% (p <0.001).

Chemotherapy 97

Chemotherapy Mayo Clinic Hospitals 97

BioPharm

JULY 1, 2024

EMA has accepted GSK’s application seeking treatment with Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

Chemotherapy 52

Chemotherapy 52

STAT

JANUARY 17, 2024

The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.

Chemotherapy 122

Chemotherapy 122

Fierce Pharma

JULY 21, 2023

This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines In this episode of "The Top Line," we talk with Vimala Raghavendran, the vice president of informatics and product development at U.S.

Chemotherapy 94

Chemotherapy 94

Drug Topics

SEPTEMBER 6, 2022

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

Chemotherapy 98

Chemotherapy 98

Pharmacy Times

DECEMBER 12, 2023

Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

OCTOBER 25, 2023

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both polymerase chain reaction and major pathologic response rates.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

OCTOBER 25, 2023

Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Chemotherapy 65

Chemotherapy 65

Pharmaceutical Technology

MAY 29, 2024

A team at King’s College London has developed a “drug delivery cage” that can be filled with chemotherapy drugs.

Chemotherapy 52

Chemotherapy 52

STAT

OCTOBER 19, 2023

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.     The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.

Chemotherapy 123

Chemotherapy 123

Fierce Pharma

SEPTEMBER 27, 2023

It’s been about 10 months since FDA inspectors rebuked a | As some cancer centers struggle to secure access to key platinum-based chemotherapies, a national spotlight gives the issue newfound political importance. But will this be a turning point for the recurrent shortage issue? ASCO's Julie Gralow, M.D., certainly hopes so.

Chemotherapy 107

Chemotherapy FDA 107

Pharmacy Times

OCTOBER 24, 2023

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

Chemotherapy 65

Chemotherapy 65

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 8 drugs in development for Chemotherapy-Induced Diarrhea (CID) by seven companies/universities/institutes. The top development phase for Chemotherapy-Induced Diarrhea (CID) is preclinical, with two drugs in that stage.

Chemotherapy 40

Chemotherapy 40

Pharmafile

MARCH 3, 2023

Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy. read more

Chemotherapy 83

Chemotherapy Communication 83

Pharmacy Times

DECEMBER 8, 2023

In an interview at the 2023 San Antonio Breast Cancer Symposium, Ana Ferrigno Guajardo, MD, discussed research into the safety and efficacy of taxane-based chemotherapy use in pregnant patients with breast cancer.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

MARCH 27, 2024

Benefits throughout post-progression endpoints and outcomes were reported for osimertinib in combination with chemotherapy.

Chemotherapy 50

Chemotherapy 50

Pharmaceutical Commerce

FEBRUARY 19, 2024

Tagrisso (osimertinib) approved for use in combination with platinum-based chemotherapy in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Chemotherapy 52

Chemotherapy FDA 52

Hospital Pharmacy Europe

FEBRUARY 14, 2023

The use of neoadjuvant chemotherapy has been shown to be of value at reducing tumour size and stage in patients with other operable cancers such as gastric and lower oesophageal adenocarcinomas. Neoadjuvant chemotherapy and cancer surgery outcomes A total of 686 patients assigned to NAC and 351 control patients were included in the analysis.

Chemotherapy 52

Chemotherapy Hospitals 52

Pharmacy Times

JANUARY 11, 2024

A majority of patients who received first-line chemotherapy switched to amivantamab-vmjw plus chemotherapy as second-line therapy.

Chemotherapy 65

Chemotherapy 65

PharmExec

MARCH 7, 2024

Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in patients with unresectable or metastatic urothelial carcinoma.

Chemotherapy 52

Chemotherapy FDA 52

Pharmacy Times

AUGUST 4, 2023

The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

JUNE 21, 2022

Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.

Chemotherapy 65

Chemotherapy 65

PharmExec

NOVEMBER 17, 2023

Merck's pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy approved for the first-line treatment of patients with locally advanced unresectable or metastatic, HER2-negative GEJ adenocarcinoma.

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

FEBRUARY 10, 2021

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

Chemotherapy 98

Chemotherapy Hospitals 98